Park K, Lewanski C, Gadgeel SM, et al. 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR). 18th World Conference on Lung Cancer (WCLC) 2017, abstract MA 10.03.
Cetuximab of cisplatine bij HPV-positief hoofd-halscarcinoom?
feb 2019 | Hoofd-halsoncologie, Radiotherapie